UK prescription charge changes announced

10 March 2008

The UK government has announced a L0.25 ($0.50) increase in the prescription charge, a levy on drugs in England, to reach L7.10 effective April 1. Health Minister Dawn Primarolo said: "In England, 88% of prescription items are free of charge thanks to our extensive exemption arrangements."

Ms Primarolo added that the revenue from the levy is expected to be L435.0 million in the 2008-2009 fiscal year. In addition, some dispensing physicians collect payments that are kept by the local health authorities. Prepaid discount vouchers are also facing increases to L27.85 for three months and L102.50 for a year. The government claims that these offer rebates for 5% of National Health Service patients. However, for a patient with 15 prescriptions a year, the saving is under 4%, having paid in advance and with no refund for part use.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight